Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Not yet recruiting · NCT06429150 · Registry updated 2026-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, plasmacytoma, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT06429150 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shenzhen Geno-Immune Medical Institute | 43 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Shenzhen | China | 39 |